Visual function disorder improving agents containing rho kinase inhibitors
CA 2443918 C · Owner: Mitsubishi Pharma Corporation · Inventors: Uehata, Masayoshi; Yoshida, Yukuo; Takayama, Yoshiko
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Visual function improving agents containing compounds having an Rho kinase inhibitory activity, in particular (R)-(+)-N-(1H-pyrrolo2,3-bpyridin-4-yl)-4- (1-aminoethyl)benzamide, as the active ingredient. Because of having effects of promoting axon extension in retinal gangliocytes and promoting regeneration of optic nerve cells, these agents are useful in treating visual function errors in association with various eye diseases caused by damage defect, degeneration, etc. in retina and optic nerve.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 11, 2002 and granted June 5, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 11, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 11, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.